Nestle's Prometheus Buy Signals Nutrition Companies in Personalized Healthcare Concept
Press Release Source: Kalorama Information On Thursday July 21, 2011, 12:13 pm EDT
NEW YORK, NY–(Marketwire – 07/21/11) – Nestlé's recent announcement that it will acquire Prometheus Laboratory in a $567 million deal marks the food giant's entry into the pathology lab testing and pharmaceutical market. But according to Kalorama Information, it's not surprising and there's likely to be more of these types of deals. The healthcare market research firm has been watching the personalized medicine concept move from promise to reality, and forecasted more acquisitions in its recent title, "World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not."
Prometheus specializes in diagnostics and specialty pharmaceutical products in oncology and gastroenterology, and in particular for inflammatory bowel diseases, such as Crohn's and ulcerative colitis. Its diagnostic products reveal genetic mutation markers that give physicians a personalized profile of these diseases for each patient.
"Why would the largest food company in the world buy a pathology lab?" asked Bruce Carlson, Publisher of Kalorama Information. "It's because they seek to join in the personalized medicine trend of targeting treatment to patients and expand the concept to nutrition."
Nestlé indicated that its purchase of Prometheus puts it in a position to build "personalized healthcare solutions based on diagnostics, pharma and nutrition," according to Nestlé Health Science CEO Luis Cantarell in a statement.
The growth in genetic data and molecular diagnostics not only opens up possibilities in personalized diagnostics and treatment, but it also opens new channels in healthcare. Nestlé's aim is to develop new clinical nutrition products that work in conjunction with clinical tests, so physicians can tailor treatments to not only include pharmaceutical drugs, but also the most appropriate nutrition products based on the results of medical tests. This might help growth for the clinical nutrition products which Kalorama currently forecasts will grow by almost 6% through 2015 in its recent research report on the topic.
Aside from the synergies, Carlson said the business itself is attractive on its own merits. "It also doesn't hurt that growth rates on test services are higher than the conventional approach of test kit selling, something we've noted in our reports in the last few years."
Kalorama Information's titles, "Clinical Nutrition Products, 4th Edition" and "World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not," give expert insights into these markets, with detailed analysis of the latest trends and developments. These market studies provide segmented market data and growth forecasts for world markets, discuss products on the market and in development, profile key industry players, and much more.
About Kalorama Information
Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter and LinkedIn.